Program
June 10, 2021
Welcome and Opening Remarks
Description
- Richard J Willke, PhD, Chief Science Officer, ISPOR, Lawrenceville, NJ, USA
June 10, 2021
Session 1: Expanding the Use of Patient and Societal Considerations in Value Assessment
Description
In recent years there has been growing awareness and research about how patients and/or society value treatments in ways that have not been included in standard cost-effectiveness analysis. This session will feature ongoing research in several of these areas, including work to improve the way child health and related societal benefit is measured, valued, and reflected in the assessment of QALY, approaches to capturing health equity and social equity considerations, and engaging patients in evaluation to better capture disease-specific considerations.
Moderator
Alan J. Balch, PhD, CEO, Patient Advocate Foundation and National Patient Advocate, Foundation, Washington, DC, USA
June 10, 2021
Break
June 10, 2021
Session 2: Incorporation of Uncertainty and Risk Aversion into Value Assessment
Description
- While it is well-known that patients often do not weight potential health gains and losses equally, our use of health state utilities and QALYs often assumes that they do. This session will feature recent work that helps us understand the nature of risk preferences in health care choices and how to estimate how those preferences may affect patient valuations. It will help bridge technical advances in this area to their application in modeling and their role in decision-making.
Moderator
Louis P. Garrison, Jr. PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, and Adjunct Professor, the Departments of Global Health and Health Services, University of Washington, Seattle, WA, USA.
June 10, 2021
Break
June 10, 2021
Session 3: Value Assessment in Decision-making
Description
- All the work on value assessment in the last 5-10 years has given health care decision-makers more to think about - but how much impact has it had? This panel session of those involved in health technology assessment and coverage and reimbursement decisions will discuss how value measures, both standard and novel, may come into play in their deliberations. It will provide insights for researchers into how their work may best be structured to be relevant for real-world decision-making.
Moderator
Edmund Pezalla, MD, MPH, Founder and CEO, Enlightenment Bioconsult, Daytona Beach, FL, USA
June 10, 2021
Closing Remarks
Description
- Adrian Towse, MA, MPhil, Office of Health Economics (OHE)